Holen Sie sich die Stockscreener-App
21.93
1.20%
0.26
Vorhandelsmarkt:
22.09
0.16
+0.73%
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Denali Therapeutics Inc. (NASDAQ:DNLI) Short Interest Up 5.1% in December - MarketBeat
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - MSN
Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
JPMorgan Chase & Co. Purchases 14,324 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Denali Therapeutics sees cash runway into 2028 - MSN
Why Is Denali Therapeutics Stock Trading Higher On Wednesday? - Benzinga
Denali Therapeutics (NASDAQ:DNLI) Stock Price Up 9.8%Still a Buy? - MarketBeat
Denali Therapeutics' (DNLI) Outperform Rating Reaffirmed at William Blair - MarketBeat
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints - MSN
Denali Therapeutics Announces Key Anticipated 2025 - GlobeNewswire
Denali's Tividenofusp Alfa Earns FDA Breakthrough Status for Hunter Syndrome, BLA Filing Set for 2025 - StockTitan
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Denali Therapeutics CEO Ryan Watts sells $750,955 in stock By Investing.com - Investing.com Nigeria
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More - MSN
Denali Therapeutics director Steve Krognes sells $69,484 in stock By Investing.com - Investing.com Australia
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains (NASDAQ:DNLI) - Seeking Alpha
Denali Therapeutics' chief medical officer Carole Ho sells $308,290 in stock By Investing.com - Investing.com South Africa
HC Wainwright Has Positive Forecast for DNLI FY2026 Earnings - MarketBeat
Denali therapeutics’ CFO Alexander Schuth sells shares worth $308,290 By Investing.com - Investing.com Nigeria
Denali therapeutics' CFO Alexander Schuth sells shares worth $308,290 By Investing.com - Investing.com Canada
Denali therapeutics' CFO Alexander Schuth sells shares worth $308,290 - Investing.com India
Denali Therapeutics CEO Ryan Watts sells $750,955 in stock - Investing.com India
Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Carole Ho Sells 12,255 Shares - MarketBeat
Ryan J. Watts Sells 29,266 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock - MarketBeat
Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 3,339 Shares of Stock - MarketBeat
Denali Therapeutics' chief medical officer Carole Ho sells $308,290 in stock - Investing.com
Denali Therapeutics director Steve Krognes sells $69,484 in stock - Investing.com
Denali Therapeutics stock maintains buy rating on FDA decision By Investing.com - Investing.com Canada
Denali Therapeutics (NASDAQ:DNLI) Trading Up 3.1%Here's What Happened - MarketBeat
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results - BioPharma Dive
Denali Therapeutics stock maintains buy rating on FDA decision - Investing.com
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases - BioSpace
Research Analysts Offer Predictions for DNLI FY2028 Earnings - MarketBeat
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) - Marketscreener.com
Denali receives FDA breakthrough status for Hunter syndrome drug - Investing.com India
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy - GlobeNewswire
Denali Therapeutics (NASDAQ:DNLI) Raised to Strong-Buy at Baird R W - MarketBeat
Denali's Hunter Syndrome Drug Gets FDA Breakthrough Status, Accelerating Path to Approval - StockTitan
Denali Therapeutics price target lowered to $32 from $35 at BTIG - Yahoo Finance
Baird starts Denali Therapeutics stock with Outperform rating By Investing.com - Investing.com Australia
Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment - Yahoo! Voices
Denali Therapeutics (NASDAQ:DNLI) Given New $24.00 Price Target at JPMorgan Chase & Co. - MarketBeat
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):